FECHA02/06/2017 - 06/06/2017
LUGAR DE REALIZACIÓNChicago, USA
FECHA09/05/2017
LUGAR DE REALIZACIÓNAuditorium, Dexeus University Hospital
FECHA06/04/2017
LUGAR DE REALIZACIÓNCologne, Germany
Resistance to next-generation EGFR-inhibitors: consequences for clinical trial design Rosell R, MD, PhD
Overcoming resistance to targeted drugs: the clinical perspective Rosell R, MD, PhD
FECHA01/04/2017 - 05/04/2017
LUGAR DE REALIZACIÓNWashington, USA
Routine Testing for KRAS mutations in cfDNA from blood of advanced cancer patients Garzón M, Mayo C, Jordana Ariza N, Balada i Bel A, García B, Villatoro S, Bertrán Alamillo J, Martínez Bueno A, Viteri Ramirez S, Pérez Rosado A, Morales Espinosa D, José Catalán M, Karachaliou N, Molina Vila M.A, Rosell R.
Analysis of EML4-ALK fusion transcripts in plasma and platelets to monitor response to crizotinib in EML4-ALK positive non-small cell lung cancer patients Aguado C, Teixidó C, Giménez-Capitán A, de los Llanos Gil M, Rodríguez S, Karachaliou N, Viteri S, Peg V, Aldeguer E, Alonso L, Rosell R, Molina-Vila M.A
Tumor cells with acquired resistance to EGFR inhibitors and overexpression or activation of AXL, MET and FGFR1 are insensitive to single-agent treatment targeting AXL, MET or FGFR Bertran-Alamillo J, Molina-Vila M.A, Teixidó C, Codony-Servat J, Giménez-Capitán J, Codony-Servat C, García-Román S, Aldeguer E, Rodríguez S, Rosell R
MET exon 14 skipping mutations in advanced non-small cell lung cancer (NSCLC) are not associated with MET amplification and overexpression Giménez-Capitán A, Teixidó C, Rodríguez S, Aguado C, Bertran-Alamillo J, Castellví J, Yeste Z, Perez A, Rosell R, Molina-Vila M.A
FECHA20/03/2017 - 23/03/2017
LUGAR DE REALIZACIÓNDr. Rosell Oncology Institute